CA3188489A1 — Inhaler system
Assigned to Norton Waterford Ltd · Expires 2022-01-06 · 4y expired
What this patent protects
A system may include a plurality of inhalers, where each inhaler comprising medicament, a processor, memory, and a transmitter, multiple processing modules that may reside at least partially on a user device, a digital health platform (DHP) that is configured to receive and aggre…
USPTO Abstract
A system may include a plurality of inhalers, where each inhaler comprising medicament, a processor, memory, and a transmitter, multiple processing modules that may reside at least partially on a user device, a digital health platform (DHP) that is configured to receive and aggregate inhaler data from inhalers that are associated with a plurality of different users and a plurality of different medicament types. The DHP may determine a subset of the usage events based on the selected medication type, the selected time of day, and/or the selected date range. The DHP may determine a filtered list of users out of the plurality of users based on a comparison of the selected inhalation count threshold with the number of usage events that are associated with the same user and medication type.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.